Literature DB >> 8107110

The crystal structure of affinity-matured human growth hormone at 2 A resolution.

M H Ultsch1, W Somers, A A Kossiakoff, A M de Vos.   

Abstract

A variant of human growth hormone (hGH), in which 15 mutations were introduced with phage display mutagenesis to improve receptor binding affinity by 400-fold, yielded two related crystal forms diffracting to high resolution. The structure of this variant was determined in both crystal forms, one at 2.0 A resolution and one at 2.4 A resolution, using molecular replacement with wild-type hGH taken from the receptor complex structure as a search model. Crystallographic refinement of the 2 A structure gave an R-value R-value of 18.5% for data in the resolution range 8 to 2 A. The final model consists of residues 1 to 128 and 155 to 191, with three side-chains modeled in alternative conformations, together with 77 water molecules. Comparison of the structure with wild-type hGH shows that most of the secondary structural elements are unchanged. The exception is the first turn of the third helix in the four-helix bundle core, which is unraveled in the present variant. Analysis of the two related packing environments suggests that this change is caused by crystal packing forces. A large change in the orientation of a short segment of helix found in the connection between the first two core helices is interpreted as evidence for rigid-body variability of this helical segment. Analysis of the mutations in light of the structure of the wild-type hGH/receptor complex shows that six of the mutations are buried in the hormone, whereas the remaining nine involve residues that interact with the receptor in the complex.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8107110     DOI: 10.1006/jmbi.1994.1135

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  12 in total

1.  High pressure fosters protein refolding from aggregates at high concentrations.

Authors:  R J St John; J F Carpenter; T W Randolph
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

2.  Stabilizing peptide fusion for solving the stability and solubility problems of therapeutic proteins.

Authors:  Eui Nam Lee; Young Mok Kim; Hye Ja Lee; Sang Woo Park; Han Young Jung; Jae Myun Lee; Yong-Ho Ahn; Jongsun Kim
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

3.  Quantitative assessment of protein structural models by comparison of H/D exchange MS data with exchange behavior accurately predicted by DXCOREX.

Authors:  Tong Liu; Dennis Pantazatos; Sheng Li; Yoshitomo Hamuro; Vincent J Hilser; Virgil L Woods
Journal:  J Am Soc Mass Spectrom       Date:  2011-10-20       Impact factor: 3.109

4.  Structural and sequence characteristics of long alpha helices in globular proteins.

Authors:  S Kumar; M Bansal
Journal:  Biophys J       Date:  1996-09       Impact factor: 4.033

Review 5.  Interleukin-6: structure-function relationships.

Authors:  R J Simpson; A Hammacher; D K Smith; J M Matthews; L D Ward
Journal:  Protein Sci       Date:  1997-05       Impact factor: 6.725

Review 6.  Comparison of the intermediate complexes of human growth hormone bound to the human growth hormone and prolactin receptors.

Authors:  A A Kossiakoff; W Somers; M Ultsch; K Andow; Y A Muller; A M De Vos
Journal:  Protein Sci       Date:  1994-10       Impact factor: 6.725

7.  Two wrongs can make a right: dimers of prolactin and growth hormone receptor antagonists behave as agonists.

Authors:  John F Langenheim; Dunyong Tan; Ameae M Walker; Wen Y Chen
Journal:  Mol Endocrinol       Date:  2005-11-03

8.  Conformational stabilization of ubiquitin yields potent and selective inhibitors of USP7.

Authors:  Yingnan Zhang; Lijuan Zhou; Lionel Rouge; Aaron H Phillips; Cynthia Lam; Peter Liu; Wendy Sandoval; Elizabeth Helgason; Jeremy M Murray; Ingrid E Wertz; Jacob E Corn
Journal:  Nat Chem Biol       Date:  2012-11-25       Impact factor: 15.040

9.  Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling.

Authors:  G Paonessa; R Graziani; A De Serio; R Savino; L Ciapponi; A Lahm; A L Salvati; C Toniatti; G Ciliberto
Journal:  EMBO J       Date:  1995-05-01       Impact factor: 11.598

Review 10.  Nanomedicines in the treatment of acromegaly: focus on pegvisomant.

Authors:  Ferdinand Roelfsema; Nienke R Biermasz; Alberto M Pereira; Johannes Romijn
Journal:  Int J Nanomedicine       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.